XyloCor Therapeutics bags US$17m in Series A financing
LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
BioFIT: innovation and investors
/in News/by Thomas GabrielczykFor two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number […]
Uncommon mutations affect breast cancer prognosis
/in News/by Thomas GabrielczykUncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
Argenx in US$1.6bn deal with J&J affiliate Janssen
/in News/by Thomas GabrielczykJanssen affiliate Cilag GmbH International has licenced argenx anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Driver of GVHD after blood stem cell transplantation identified
/in News/by Thomas GabrielczykSwiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
Investors pool 27m for new Proteomics tech
/in News/by Thomas GabrielczykUK-based biotech startup Fluidic Analytics has raised 27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus […]
Carbios set to build closed-loop PET plant
/in News/by Thomas GabrielczykFrench Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation […]
Adrenomed bags 24m in growth financing
/in News/by Thomas GabrielczykGerman Adrenomed AG has bagged 24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Roche targets asthma with inhalable JAK1 blocker
/in News/by Thomas GabrielczykResearchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
British F2G Biotech bags 24m
/in News/by Thomas GabrielczykThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd 24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).